OverviewShareholderFinancial highlightsOur strategy
Download PDF

Annual Report Overview 2019

Innovating antibodies, improving lives

Genmab In Short

Genmab is an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.

2* Approved Products in Collaboration

DARZALEX® marketed in the U.S., Europe, Japan and multiple other countries; Arzerra® marketed in the U.S. and Japan

6 Proprietary** Antibody Products in Clinical Development

Tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5 (GEN1029), epcoritamab (DuoBody-CD3xCD20), DuoBody-PD-L1x4-1BB (GEN1046) and DuoBody-CD40x4-1BB (GEN1042)

4 Proprietary Technologies

DuoBody® platform, HexaBody® platform, DuoHexaBody® platform & HexElect® platform

2 Categories of Cancer

Generate products to treat solid tumors and hematological cancers

~20 Pre-clinical Projects

Extensive partnered and own pre-clinical pipeline

35 INDs

Investigational new drug applications filed by Genmab and partners since 1999

1 / 6

2* Approved Products in Collaboration

DARZALEX® marketed in the U.S., Europe, Japan and multiple other countries; Arzerra® marketed in the U.S. and Japan

6 Proprietary** Antibody Products in Clinical Development

Tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5 (GEN1029), epcoritamab (DuoBody-CD3xCD20), DuoBody-PD-L1x4-1BB (GEN1046) and DuoBody-CD40x4-1BB (GEN1042)

4 Proprietary Technologies

DuoBody® platform, HexaBody® platform, DuoHexaBody® platform & HexElect® platform

2 Categories of Cancer

Generate products to treat solid tumors and hematological cancers

~20 Pre-clinical Projects

Extensive partnered and own pre-clinical pipeline

35 INDs

Investigational new drug applications filed by Genmab and partners since 1999

* In January 2020, teprotumumab approved as TEPEZZA™ in U.S.
** Tisotumab vedotin 50:50 partner with Seattle Genetics, DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB 50:50 partner with BioNTech

Shareholder letter

“We more than accomplished our goals with our extremely successful IPO in the U.S.”

– Jan van de Winkel, Ph.D. President & CEO
Read the shareholder letter
Jan van de Winkel, Ph.D. President & CEO

Financial Highlights

Revenue
Operating Expenses
Operating Result
DKK million

2015
2016
2017
2018
2019

Our Vision

By 2025, our own product has transformed cancer treatment, and we have a pipeline of knock-your-socks-off antibodies

Our Three-pronged Strategy

Focus on core competence

Turn science into medicine

Build a profitable and successful biotech

2020 outlook and key priorities

Our 2020 outlook and key priorities are designed to advance our pipeline, deliver on our promise for patients and create value as we work toward our 2025 vision

Read more
Contact
Marisol Peron
Corporate Vice President
Communications & Investor Relations
T: +1 609 524 0065
E: mmp@genmab.com
© 2020 Genmab A/S
Investor Relations Contact
Andrew Carlsen
Senior Director
Investor Relations
T: +45 33 77 95 58
E: acn@genmab.com